Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × utomilumab × Clear all
NCT02951156 2020-12-17

Javelin DLBCL

Pfizer

Phase 3 Terminated
29 enrolled 24 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01307267 2020-03-17

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Pfizer

Phase 1 Completed
190 enrolled 65 charts
DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡